Neuralstem (AMEX: CUR) Ischemic Stroke Program in China
Under the agreement, BaYi Brain and CUR will jointly prepare a clinical protocol for treatment of motor deficits due to ischemic stroke.
- “BaYi Brain will prepare the Mandarin version of the clinical trial documents and submit the documents to the Hospital’s Ethics Board for review and approval. Upon approval of the trial protocol by the Hospital’s Ethics Board, BaYi Brain then submits the documents to the Military Regulatory Agency for review and approval of the trial. BaYi Brain will be the site of the trial, which CUR will sponsor”.
The Bottom Line: Still trying to decipher the news worthiness of this “signed” memorandum of understanding that has to be prepared, translated, submitted, reviewed, ethics board approved, submitted to the MILITARY regulatory agency’s board, approved again and then initiation for recruitment. AMEX:CUR in a “deal” that will cost them dollars, got $0.17 or a 10% in its stock pricing to $1.87. Tell me when it’s done, what the cost, ROI, clinical relevance and data will be … it will slip.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.